Key benefits of attending:Learn about health technology assessment protocols and market access in the EU and globallyNetwork with key regulators of orphan medicines and policy makers for national rare disease treatmentDiscover successful funding, financing and economic models for orphan drug development and translational researchAnalyse industry case studies showing how R&D and market access costs can be reducedUnderstand the latest developments in ultra-rare diseases studies and new medicines for themExplore how organisations are merging research, resources and expertise in the race to cure rare diseases Hear keynote addresses from:Dr. Edmund Jessop, Medical Advisor, National Commissioning Group for Highly Specialised Services, NHS        Josie Godfrey, Head of Policy and Coordination, AGNSSStephen Nutt, Executive Officer, Rare Disease UK Carlos R. Camozzi, MD, PhD, MBA, Vice President, Chief Medical Officer, uniQure B.V.Marisa Jaconi, Vice-Director and Founder, Swiss Institute of Cell Therapies (SICT)Samantha Parker, Director of External Affairs and Rare Disease Partnerships, Orphan Europe